宫颈癌和子宫内膜癌术后质子束放疗后健康相关生活质量和患者报告症状:前瞻性II期APROVE试验的2年结果
APROVE试验前瞻性纳入25例宫颈癌或子宫内膜癌术后患者,接受单纯质子放疗或联合化疗,评估健康相关生活质量和患者报告症状至放疗后2年。总体健康状况基线受损,2年后显著改善至与年龄匹配参考人群相当;子宫内膜癌患者疼痛和胃肠道症状有急性和长期加重,但无CTCAE≥3级毒性;宫颈癌患者更常出现淋巴水肿;性功能障碍仍是重要问题。
要点
- 质子束术后放疗耐受性良好,仅低级别胃肠道症状、淋巴水肿和疼痛。
- 总体健康状况从基线均值58.0±20.1显著改善至2年时69.9±19.3(p=0.036)。
- 子宫内膜癌患者疼痛(p=0.048)和胃肠道症状(p=0.016)有急性和长期加重,但无CTCAE≥3级毒性。
核心结论
- 质子束术后放疗耐受性良好,仅出现低级别胃肠道症状、淋巴水肿和疼痛。
- 总体生活质量基线受损,但患者2年后恢复至与参考人群相当的水平。
- 需要更大规模的研究来确认质子治疗的获益是否能转化为临床效应。
- 性功能障碍仍是重要问题。
研究设计与样本
- 前瞻性II期APROVE试验纳入25例宫颈癌或子宫内膜癌术后患者,接受单纯质子放疗或联合化疗。
- 采用EORTC-QLQ-C30联合QLQ-CX24(宫颈癌)和QLQ-EN24(子宫内膜癌)问卷,在基线、放疗结束时及放疗后2年内评估健康相关生活质量。
- 症状采用常见不良事件评价标准(CTCAE)和机构患者报告症状分级评估。
- 结果与年龄匹配的常模参考人群比较。
主要发现
- 总体健康状况基线均值58.0±20.1,较参考人群明显受损,2年后显著改善至均值69.9±19.3(p=0.036),与常模值相当。
- 子宫内膜癌患者疼痛(p=0.048)和胃肠道症状(p=0.016)出现急性和长期加重,但未观察到CTCAE≥3级毒性。
- 直肠、乙状结肠、大肠和小肠的剂量学评估与报告的胃肠道症状无相关性。
- 2年后疲劳显著改善(p=0.030),而宫颈癌患者更常出现淋巴水肿(p=0.017)。
- 子宫内膜癌患者性活动(p=0.048)和身体意象(p=0.022)评分在治疗后改善,身体意象改善在2年后持续存在。
局限性
- 需要更大规模的研究来确认质子治疗的获益是否能转化为临床效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The APROVE-trial investigated the tolerability of postoperative proton beam therapy in women with cervical or endometrial cancer. The present analysis evaluated the secondary endpoints of health-related quality of life (HRQOL) and patient-reported symptoms. METHODS: 25 patients were included in this prospective phase-II-trial and treated with postoperative radiotherapy using protons alone or in combination with chemotherapy. To attain general and gynecologic-specific HRQOL measures, the EORTC-QLQ-C30 questionnaires combined with -QLQ-CX24 for cervical and -QLQ-EN24 for endometrial cancer were assessed at baseline, at the end of RT and up to 2 years after radiotherapy. The results were compared to an age-matched norm reference population. Symptoms were assessed using Common Terminology Criteria for Adverse Events (CTCAE) and institutional patient-reported symptoms grading. RESULTS: Scores regarding global health status were markedly impaired at baseline (mean: 58.0 ± 20.1) compared to reference population data, but significantly (p = 0.036) improved and evened out to comparable norm values 2 years after proton therapy (mean: 69.9 ± 19.3). Treatment caused acute and long-term worsening of pain (p = 0.048) and gastrointestinal symptoms (p = 0.016) for women with endometrial cancer, but no higher-grade CTCAE ≥ 3° toxicity was observed. Dosimetric evaluation of rectum, sigmoid, large and small bowel showed no correlation with the reported gastrointestinal symptoms. After 2 years, fatigue had significantly improved (p = 0.030), whereas patients with cervical cancer experienced more often lymphedema (p = 0.017). Scores for endometrial cancer pertaining to sexual activity (p = 0.048) and body image (p = 0.022) had improved post treatment; in the latter this effect persisted after 2 years. CONCLUSION: Proton beam therapy in the adjuvant setting was well tolerated with only low-grade side effects concerning gastrointestinal symptoms, lymphedema and pain. Overall quality of life was impaired at baseline, but patients were able to recover to values comparable to norm population 2 years after proton therapy. Larger studies are needed to confirm whether the benefit of proton therapy translates into a clinical effect. Sexual dysfunction remains an important issue. TRIAL REGISTRATION: The trial was registered at https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT03184350, 09th June 2017).
引用
- Meixner E, Wark A, Forster T, et al. Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial. Radiat Oncol. 2023. PMID: 36624483. doi:10.1186/s13014-023-02198-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。